AAAAAA
Results: 26-50/55
Authors:
Pierce, LJ
Strawderman, M
Narod, SA
Oliviotto, I
Eisen, A
Dawson, L
Gaffney, D
Solin, LJ
Nixon, A
Garber, J
Berg, C
Isaacs, C
Heimann, R
Olopade, OI
Haffty, B
Weber, BL
Citation: Lj. Pierce et al., Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations, J CL ONCOL, 18(19), 2000, pp. 3360-3369
Authors:
Narod, SA
Brunet, JS
Ghadirian, P
Robson, M
Heimdal, K
Neuhausen, SL
Stoppa-Lyonnet, D
Lerman, C
Pasini, B
de los Rios, P
Weber, B
Lynch, H
Citation: Sa. Narod et al., Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study, LANCET, 356(9245), 2000, pp. 1876-1881
Authors:
Lerman, C
Hughes, C
Croyle, RT
Main, D
Durham, C
Sndyer, C
Bonney, A
Lynch, JF
Narod, SA
Lynch, HT
Citation: C. Lerman et al., Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing, PREV MED, 31(1), 2000, pp. 75-80
Authors:
Goshen, R
Chu, W
Elit, L
Pal, T
Hakimi, J
Ackerman, I
Fyles, A
Mitchell, M
Narod, SA
Citation: R. Goshen et al., Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?, GYNECOL ONC, 79(3), 2000, pp. 477-481
Authors:
Nam, RK
Elhaji, Y
Krahn, MD
Hakimi, J
Ho, M
Chu, W
Sweet, J
Trachtenberg, J
Jewett, MAS
Narod, SA
Citation: Rk. Nam et al., Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression, J UROL, 164(2), 2000, pp. 567-572
Authors:
Metcalfe, KA
Liede, A
Hoodfar, E
Scott, A
Foulkes, WD
Narod, SA
Citation: Ka. Metcalfe et al., An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling, J MED GENET, 37(11), 2000, pp. 866-874
Authors:
Liede, A
Pal, T
Mitchell, M
Narod, SA
Citation: A. Liede et al., Delineation of a new syndrome: clustering of pyloric stenosis, endometriosis, and breast cancer in two families, J MED GENET, 37(10), 2000, pp. 794-796
Authors:
Hamel, N
Karimi, S
Hebert-Blouin, MN
Brunet, JS
Gilfix, B
Ghadirian, P
Black, MJ
Narod, SA
Foulkes, WD
Citation: N. Hamel et al., Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco, INT J CANC, 87(3), 2000, pp. 452-454
Authors:
Kuperstein, G
Foulkes, WD
Ghadirian, P
Hakimi, J
Narod, SA
Citation: G. Kuperstein et al., A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, CLIN GENET, 57(3), 2000, pp. 213-220
Authors:
Vassilikos, EJK
Yu, H
Trachtenberg, J
Nam, RK
Narod, SA
Bromberg, IL
Diamandis, EP
Citation: Ejk. Vassilikos et al., Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up, CLIN BIOCH, 33(2), 2000, pp. 115-123
Authors:
Lal, G
Liu, G
Schmocker, B
Kaurah, P
Ozcelik, H
Narod, SA
Redston, M
Gallinger, S
Citation: G. Lal et al., Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations, CANCER RES, 60(2), 2000, pp. 409-416
Authors:
Liede, A
Cohen, B
Black, DM
Davidson, RH
Renwick, A
Hoodfar, E
Olopade, OI
Micek, M
Anderson, V
De Mey, R
Fordyce, A
Warner, E
Dann, JL
King, MC
Weber, B
Narod, SA
Steel, CM
Citation: A. Liede et al., Evidence of a founder BRCA1 mutation in Scotland, BR J CANC, 82(3), 2000, pp. 705-711
Authors:
Liu, G
Ghadirian, P
Vesprini, D
Hamel, N
Paradis, AJ
Lai, G
Gallinger, S
Narod, SA
Foulkes, WD
Citation: G. Liu et al., Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma, BR J CANC, 82(10), 2000, pp. 1646-1649
Authors:
Liede, A
Metcalfe, K
Hanna, D
Hoodfar, E
Snyder, C
Durham, C
Lynch, HT
Narod, SA
Citation: A. Liede et al., Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling, AM J HU GEN, 67(6), 2000, pp. 1494-1504
Authors:
Mazoyer, S
Leary, J
Kirk, J
Fleischmann, E
Wagner, T
Claes, K
Messiaen, L
Foulkes, W
Desrochers, M
Simard, J
Phelan, CM
Kwan, E
Narod, SA
Vahteristo, P
Nevanlinna, H
Durando, X
Bignon, YJ
Peyrat, JP
Bonnardel, C
Sinilnikova, OM
Puget, N
Lenoir, GM
Mazoyer, S
Audoynaud, C
Goldgar, D
Maugard, C
Caux, V
Gad, S
Stoppa-Lyonnet, D
Nogues, C
Lidereau, R
Machavoine, C
Bressac-de Paillerets, B
Kuschel, B
Betz, B
Niederacher, D
Beckmann, MW
Hamann, U
Gayther, SA
Ponder, BAP
Robinson, M
Taylor, GR
Bishop, T
Catteau, A
Solomon, E
Cohen, B
Steel, M
Collins, N
Stratton, M
van der Looij, M
Olah, E
Miller, NJ
Barton, DE
Sverdlov, RS
Friedman, E
Radice, P
Montagna, M
Sensi, E
Caligo, M
van Eijk, R
Devilee, P
van der Luijt, R
Heimdal, K
Moller, P
Borg, A
Diez, O
Cortes, J
Domenech, M
Baiget, M
Osorio, A
Benitez, J
Borg, A
Maillet, P
Sappino, AP
Ozdag, H
Ozcelik, T
Ozturk, M
Rohlfs, EM
Boyd, J
McDermott, D
Offit, K
Unger, M
Nathanson, K
Weber, BL
Sellers, TA
Hampton, E
Couch, FJ
Neuhausen, S
Citation: S. Mazoyer et al., The exon 13 duplication in the BRCA1 gene is a founder mutation present ingeographically diverse populations, AM J HU GEN, 67(1), 2000, pp. 207-212
Authors:
Gorski, B
Byrski, T
Huzarski, T
Jakubowska, A
Menkiszak, J
Gronwald, J
Pluzanska, A
Bebenek, M
Fischer-Maliszewska, L
Grzybowska, E
Narod, SA
Lubinski, J
Citation: B. Gorski et al., Founder mutations in the BRCA1 gene in polish families with breast-ovariancancer, AM J HU GEN, 66(6), 2000, pp. 1963-1968
Authors:
Moslehi, R
Chu, W
Karlan, B
Fishman, D
Risch, H
Fields, A
Smotkin, D
Ben-David, Y
Rosenblatt, J
Russo, D
Schwartz, P
Tung, N
Warner, E
Rosen, B
Friedman, J
Brunet, JS
Narod, SA
Citation: R. Moslehi et al., BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer, AM J HU GEN, 66(4), 2000, pp. 1259-1272
Authors:
Rebbeck, TR
Levin, AM
Eisen, A
Snyder, C
Watson, P
Cannon-Albright, L
Isaacs, C
Olopade, O
Garber, JE
Godwin, AK
Daly, MB
Narod, SA
Neuhausen, SL
Lynch, HT
Weber, BL
Citation: Tr. Rebbeck et al., Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J NAT CANC, 91(17), 1999, pp. 1475-1479
Authors:
Boyd, J
Narod, SA
Citation: J. Boyd et Sa. Narod, Association between nonrandom X-chromosome inactivation and BRCA1 mutationin germline DNA of patients with ovarian cancer, J NAT CANC, 91(17), 1999, pp. 1507-1508
Authors:
Lynch, HT
Watson, P
Tinley, S
Snyder, C
Durham, C
Lynch, J
Kirnarsky, Y
Serova, O
Lenoir, G
Lerman, C
Narod, SA
Citation: Ht. Lynch et al., An update on DNA-Based BRCA1/BRCA2 genetic counseling in hereditary breastcancer, CANC GENET, 109(2), 1999, pp. 91-98
Authors:
Jernstrom, H
Lerman, C
Ghadirian, P
Lynch, HT
Weber, B
Garber, J
Daly, M
Olopade, OI
Foulkes, WD
Warner, E
Brunet, JS
Narod, SA
Citation: H. Jernstrom et al., Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2, LANCET, 354(9193), 1999, pp. 1846-1850
Authors:
Chappuis, PO
Narod, SA
Foulkes, WD
Citation: Po. Chappuis et al., Screening for ovarian cancer, LANCET, 354(9177), 1999, pp. 509-510
Authors:
Narod, SA
Brunet, JS
Citation: Sa. Narod et Js. Brunet, Oral contraceptives and hereditary ovarian cancer - Reply, N ENG J MED, 340(1), 1999, pp. 60-60
Authors:
van Orsouw, NJ
Dhanda, RK
Elhaji, Y
Narod, SA
Li, FP
Eng, C
Vijg, J
Citation: Nj. Van Orsouw et al., A highly accurate, low cost test for BRCA1 mutations, J MED GENET, 36(10), 1999, pp. 747-753
Authors:
Zweemer, RP
Shaw, PA
Verheijen, RMH
Ryan, A
Berchuck, A
Ponder, BAJ
Risch, H
McLaughlin, JR
Narod, SA
Menko, FH
Kenemans, P
Jacobs, IJ
Citation: Rp. Zweemer et al., Accumulation of p53 protein is frequent in ovarian cancers associated withBRCA1 and BRCA2 germline mutations, J CLIN PATH, 52(5), 1999, pp. 372-375